A 2035 Clinical Research Vision and Roadmap for High‐Risk Neuroblastoma
Despite the introduction of anti-GD2 antibody therapy, outcomes for children with high-risk neuroblastoma remain poor, with low cure rates and a high proportion of survivors facing long-term sequelae. In this report, leaders from international cooperative groups and patient advocacy organizations review lessons learnt, identify current challenges, and provide a vision to bring new agents into frontline therapy to increase cure rates and reduce long-term toxicities over the next decade. The implementation of this vision requires improved global collaboration, incorporation of novel biomarkers, and a strengthened interaction with the regulatory landscape.
Authors
- Steven G. DuBois (ORCID: https://orcid.org/0000-0003-0882-738X)
- Rochelle Bagatell (ORCID: https://orcid.org/0000-0002-5729-8819)
- Nick Bird (ORCID: https://orcid.org/0000-0003-1808-8584)
- Maja Beck‐Popovic (ORCID: https://orcid.org/0000-0001-9502-5697)
- Donna Ludwinski (ORCID: https://orcid.org/0000-0003-4717-7690)
- Leona Knox (ORCID: https://orcid.org/0000-0002-5218-3895)
- Lucas Moreno (ORCID: https://orcid.org/0000-0002-0708-1670)
- Andrew D.J. Pearson
Institutions
- Universitat Autònoma de Barcelona (ES)
- Children's Hospital of Philadelphia (US)
- Institute of Cancer Research (GB)
- Centre Hospitalier Universitaire Vaudois (CH)
- London Cancer (GB)
- Vall d'Hebron Institut de Recerca (ES)
- Solving Kids' Cancer (US)
- Vall d'Hebron Hospital Universitari (ES)
- Dana-Farber/Boston Children's Cancer and Blood Disorders Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1002/pbc.31660
- Citations
- 2
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78